As the flurry of executive orders continues to flow from the White House, leaving in its wake chaos and confusion across the ...

Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr ...

In response to the news of reported layoffs at the U.S. FDA over the weekend, Advanced Medical Association president and CEO ...

Once high-flying Bluebird Bio Inc. has found a way out of its financial squeeze, as funds managed by global investment firms ...

Gene therapy specialist Meiragtx Holdings plc is heading for its first marketing approval following the successful treatment ...

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that ...

Approxima Srl raised €7.3 million (US$7.65 million) in the first close of its series A financing round for its tricuspid valve repair system which is based on reshaping the right ventricle.

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

Using ALK+ lung cancer patient-derived cell lines, researchers have performed phosphoproteomic screening and identified ...

Photys Therapeutics Inc. has signed a license agreement with Hangzhou Polymed Biopharmaceuticals Inc. for HPB-143, a phase I-ready IRAK-4 degrader. IRAK-4 degradation offers potential to treat various ...

Thetis Pharmaceuticals LLC has presented preclinical data on their BLT1 receptor agonist TP-317 as an approach for treating inflammatory bowel disease. BLT1 activation promotes immune homeostasis and ...

Several Asia biotechs this week – including Innocare Pharma Ltd., Akeso Pharmaceuticals Inc., Sanbio Co. Ltd. and Ascletis Pharma Inc. – unveiled the start of new late-stage clinical trials or interim ...